The North America Diagnostic Tests Market is experiencing sustained expansion. Valued at USD 98.72 billion in 2024, the market is projected to reach USD 168.45 billion by 2030, growing at a CAGR of 9.30% during 2025–2030. This report provides a comprehensive analysis of market dynamics, segmentation, drivers, challenges, opportunities, and competitive landscape, drawing exclusively from Data Bridge Market Research to deliver strategic insights for stakeholders.

What Are Diagnostic Tests in North America?

Diagnostic tests include a broad spectrum of in vitro and in vivo assays used to detect, monitor, and manage diseases. Key categories:

• Laboratory-based — Clinical chemistry, immunoassays, microbiology, molecular diagnostics (PCR, NGS).
• Point-of-Care (POC) → Rapid tests, portable analyzers.
• Imaging-integrated → Companion diagnostics with radiology.
• At-home / Self-testing → Glucose, pregnancy, COVID/influenza, cholesterol.

North America leads globally due to high healthcare spending, advanced reimbursement, FDA approvals, and strong R&D ecosystem.

Market Size and Growth Projections

Chronic disease prevalence, aging population, and technological adoption drive growth. From a 2024 base of USD 98.72 billion, the market is anticipated to reach USD 168.45 billion by 2030 at 9.30% CAGR.

Source: Data Bridge Market Research

United States holds the dominant share, driven by high testing volume, reimbursement, and innovation. Canada is the fastest-growing country within North America, supported by universal healthcare expansion and public health investments.

Market Segmentation

The market is segmented to uncover high-growth areas:

By Type

• Clinical Chemistry → Largest segment.
• Immunoassays
• Molecular Diagnostics → Fastest-growing.
• Hematology
• Microbiology
• Coagulation
• Others (urinalysis, endocrinology, therapeutic drug monitoring)

By Technology

• PCR / qPCR
• Next-Generation Sequencing (NGS)
• Microarrays
• Mass Spectrometry
• Flow Cytometry
• Others

By Application

• Infectious Diseases → Dominant.
• Oncology
• Cardiology
• Diabetes
• Autoimmune Diseases
• Others (neurology, genetic disorders)

By End User

• Hospitals & Diagnostic Laboratories → Largest.
• Physician Offices / Clinics
• Home Care / Self-testing
• Academic & Research Institutes
• Others

By Country

• United States → Dominant.
• Canada → Fastest-growing.
• Mexico

Key Drivers Fueling Growth

1. High Burden of Chronic & Infectious Diseases → Diabetes, CVD, cancer, COVID-19 legacy.
2. Aging Population → Increased screening and monitoring needs.
3. Technological Advancements — POC, NGS, AI interpretation, multiplex panels.
4. Reimbursement & Insurance Coverage — Favorable policies for diagnostics.
5. Preventive Healthcare Shift → Early detection and wellness testing.

Challenges and Restraints

• High Cost of Advanced Tests — NGS, companion diagnostics.
• Reimbursement Variability — Coverage gaps for novel tests.
• Regulatory Stringency — FDA/CLIA requirements.
• Lab Workforce Shortages — Skilled technologist constraints.

Opportunities

• Point-of-Care & At-Home Testing Expansion — Rapid diagnostics.
• Precision Medicine & Companion Diagnostics — Oncology, rare diseases.
• Digital Health Integration — Telemedicine-linked testing.
• Emerging Infectious Disease Preparedness — Multiplex panels.

Competitive Landscape

The market is highly competitive, with leaders investing in automation, multiplex assays, and digital integration:

• Abbott Laboratories (U.S.)
• Roche Diagnostics (Switzerland)
• Siemens Healthineers (Germany)
• Danaher Corporation (Beckman Coulter, Cepheid) (U.S.)
• Quest Diagnostics (U.S.)
• Labcorp (U.S.)
• bioMérieux SA (France)
• Thermo Fisher Scientific (U.S.)
• Becton, Dickinson and Company (U.S.)
• bio-Rad Laboratories (U.S.)
• Hologic, Inc. (U.S.)
• QIAGEN (Netherlands)
• PerkinElmer, Inc. (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• Sysmex Corporation (Japan)

Recent developments include Abbott's 2024 Alinity multi-assay system expansions; Roche's 2025 cobas t 711 coagulation analyzer launch; and Labcorp's 2024 at-home testing platform enhancements.

Future Trends and Opportunities

By 2030, trends will emphasize at-home diagnostics, AI/ML interpretation, multiplex panels, and liquid biopsy integration. Opportunities in preventive screening, chronic disease monitoring, and emerging infectious disease preparedness.

Conclusion

The North America Diagnostic Tests Market is set for strong growth to USD 168.45 billion by 2030 at 9.30% CAGR, powering precision healthcare. Stakeholders should invest in POC and molecular solutions to overcome costs and capture preventive testing opportunities. Prioritizing U.S. reimbursement and Canada's public health investments will ensure diagnostic success.

Browse More Reports:

Global Digital Human Market
Global Passion Fruit Market
Global Skin Care Products Market
Global Diagnostic Tests Market
Global eSports Market
South America Tissue Paper Market
Global Propylene Market
Global Biosurfactants Market
Global Paper and Paperboard Packaging Market
Global Hydroxypropyl Methylcellulose (HPMC) Market
Global Protein Cookie Market
Global Hydrophonics Market
Global Aquaponics Market
Global Betanin Market
Global Burglar Alarm Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com